1. Home
  2. NXDT vs SPRO Comparison

NXDT vs SPRO Comparison

Compare NXDT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Diversified Real Estate Trust

NXDT

NexPoint Diversified Real Estate Trust

HOLD

Current Price

$3.70

Market Cap

170.0M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.32

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXDT
SPRO
Founded
2012
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.0M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NXDT
SPRO
Price
$3.70
$2.32
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
133.6K
342.0K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
9.66%
N/A
EPS Growth
N/A
N/A
EPS
0.99
N/A
Revenue
N/A
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.89
$0.51
52 Week High
$13.07
$3.22

Technical Indicators

Market Signals
Indicator
NXDT
SPRO
Relative Strength Index (RSI) 68.15 48.42
Support Level $2.65 $2.30
Resistance Level $3.70 $2.36
Average True Range (ATR) 0.26 0.08
MACD 0.11 -0.00
Stochastic Oscillator 90.04 54.17

Price Performance

Historical Comparison
NXDT
SPRO

About NXDT NexPoint Diversified Real Estate Trust

NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: